Head-to-head comparison
HealthSource vs REMEVi
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
HealthSource sells compounded semaglutide, compounded tirzepatide and a nightly sublingual tirzepatide tablet in all 50 states, charged every four weeks rather than by the calendar month.
$199 per 4 weeks sema · $299 per 4 weeks tirz · Verified August 2026
Marked down on: You pay before the medical intake — the questionnaire link appears only after checkout, and withdrawing once you have filled it in costs you $25–$45 for the provider review
Desk Score
A flat $219 a month for semaglutide and $319 for tirzepatide at every dose, lower on 12- and 24-week plans, with four named pharmacies and the whole program in English or Spanish.
$219/mo sema · $319/mo tirz · Verified August 2026
Marked down on: The flat rate is a higher entry price than teaser-led competitors
REMEVi takes this head-to-head with the higher Desk Score, 86/100 (B) against 84/100 (B) for HealthSource. HealthSource still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
HealthSource
84/100
B
REMEVi
86/100
B
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | HealthSource | REMEVi |
|---|---|---|
| Semaglutide | $199 per 4 weeks$199 every 4 weeks month-to-month (13 charges a year, all doses, compounded) | $219/mo$219/mo month-to-month; $189/mo on a 12-week plan; $179/mo on a 24-week plan; same price at every dose; oral tablet $349/mo month-to-month or $309/mo on a 12-week plan |
| Tirzepatide | $299 per 4 weeks$299 every 4 weeks month-to-month (13 charges a year, all doses, compounded) | $319/mo$319/mo month-to-month; $249/mo on a 12-week plan; $229/mo on a 24-week plan; same price at every dose; compounded injectable |
| Coverage | All 50 states | All 50 states and DC |
| Brand-name | Compounded only | Compounded only |
| Oral option | Yes | Yes |
| Best for | Compounded semaglutide or tirzepatide, by weekly injection or as a nightly tablet, in all 50 states from $199 every four weeks. | Someone who wants one price that never climbs with the dose — or a Spanish-speaking patient who wants the intake, portal and care team in their own language. |
| Desk Score | 84/100B | 86/100B |
The verdict
Desk pick — REMEViREMEVi takes this head-to-head with the higher Desk Score, 86/100 (B) against 84/100 (B) for HealthSource. HealthSource still holds its ground where its strengths line up with yours.
Choose HealthSource if…
Compounded semaglutide or tirzepatide, by weekly injection or as a nightly tablet, in all 50 states from $199 every four weeks.
$199 per 4 weeks sema · $299 per 4 weeks tirz · All 50 states
Choose REMEVi if…
Someone who wants one price that never climbs with the dose — or a Spanish-speaking patient who wants the intake, portal and care team in their own language.
$219/mo sema · $319/mo tirz · All 50 states and DC
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: HealthSource · REMEVi.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs HealthSource
- CoreAge Rx vs REMEVi
- Curex vs HealthSource
- Curex vs REMEVi
- BetterMe Rx vs HealthSource
- BetterMe Rx vs REMEVi
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.